# Open Multi-cohort Study of the First Phase of Safety of a Drug Based on Double Recombinant Vaccinia Virus VV-GMCSF-Lact

> **NCT05376527** · PHASE1 · COMPLETED · sponsor: **"Oncostar" LLC** · enrollment: 34 (actual)

## Conditions studied

- Oncolytic Virotherapy

## Interventions

- **BIOLOGICAL:** Double Recombinant Vaccinia Virus VV-GMCSF-Lact

## Key facts

- **NCT ID:** NCT05376527
- **Lead sponsor:** "Oncostar" LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-11
- **Primary completion:** 2025-02-27
- **Final completion:** 2025-02-27
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2026-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05376527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05376527, "Open Multi-cohort Study of the First Phase of Safety of a Drug Based on Double Recombinant Vaccinia Virus VV-GMCSF-Lact". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05376527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*